XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies

Saved in:
Bibliographic Details
Published in:Blood 2022-11, Vol.140 (Supplement 1), p.99-100
Main Authors: Kruer, Traci L., Quintana, Ariel, Ferrall-Fairbanks, Meghan, Zhang, Ling, Newman, Hannah, McLemore, Amy F, Yang, Qin, Bencrentsil, Nana, Komrokji, Rami S., Chaudhry, Sana, Totiger, Tulasigeri M, Figueroa, Maria Ken E., Taylor, Justin, Sallman, David A., Padron, Eric
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-169765